Research programme: antisense oligonucleotides - Roquefort Therapeutics
Latest Information Update: 09 May 2024
At a glance
- Originator Murdoch University; Roquefort Therapeutics
- Developer Roquefort Therapeutics
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Gene silencing; Midkine expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Jul 2023 Roquefort Therapeutics has patent protection for midkine oligonucleotides before July 2023
- 03 Dec 2022 Pharmacodynamics data from a preclinical trial in Cancer released by Roquefort Therapeutics
- 11 Oct 2022 Preclinical trials in Cancer in United Kingdom (Parenteral) before October 2022 (Roquefort Therapeutics website, April 2024)